AARON T BOWMAN
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology RENO, NV NPI 1356430227
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NV E.R. Squibb & Sons, L.L.C. All categories
General Payments — all program years on this page
$5,791.89
- Category: General Payments
- Program years: PY2018–2024
- Record count: 233
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,475.16 across 54 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,475.16 | 54 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $169.25 | 6 |
| Ipsen Biopharmaceuticals, Inc | $136.50 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $101.01 | 4 |
| Daiichi Sankyo Inc. | $90.10 | 4 |
| Janssen Biotech, Inc. | $78.59 | 3 |
| Acerta Pharma LLC | $72.75 | 3 |
| EISAI INC. | $63.11 | 2 |
| SpringWorks Therapeutics, Inc. | $58.26 | 2 |
| Deciphera Pharmaceuticals Inc. | $55.07 | 2 |
| SOBI, INC | $53.06 | 2 |
| Astellas Pharma US Inc | $50.91 | 2 |
| Mirati Therapeutics, Inc. | $49.99 | 2 |
| Merck Sharp & Dohme Corporation | $47.86 | 2 |
| Incyte Corporation | $45.33 | 2 |
| Genentech USA, Inc. | $45.06 | 2 |
| PFIZER INC. | $41.18 | 2 |
| Regeneron Healthcare Solutions, Inc. | $36.26 | 1 |
| Karyopharm Therapeutics Inc. | $34.43 | 1 |
| Kyowa Kirin, Inc. | $28.30 | 1 |
| PharmaEssentia USA Corporation | $27.58 | 1 |
| Alexion Pharmaceuticals, Inc. | $25.12 | 1 |
| EMD Serono, Inc. | $24.98 | 1 |
| ADC Therapeutics America, Inc. | $24.75 | 1 |
| Apellis Pharmaceuticals, Inc. | $24.65 | 1 |
| GlaxoSmithKline, LLC. | $24.35 | 1 |
| SERVIER PHARMACEUTICALS LLC | $22.94 | 1 |
| Octapharma USA, Inc. | $22.82 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $20.95 | 1 |
By program year
Records — PY2024 (54)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.